MACE (Major Adverse Cardiovascular Events)
The Phase 3 trials that won approval, and the outcome studies that came afterward on cardiovascular, kidney and sleep-apnea endpoints.
What is MACE (Major Adverse Cardiovascular Events)?
Major adverse cardiovascular events, the composite endpoint CV trials are built on, usually cardiovascular death plus nonfatal myocardial infarction plus nonfatal stroke.
SELECT showed a 20% relative reduction, SUSTAIN-6 26%, LEADER 13%. The effect tracks weight loss loosely but exceeds what weight loss alone accounts for.
Top GLP-1 cardiovascular studies →
GLP Watchdog writes these definitions from FDA labels and peer-reviewed PubMed literature.
Where MACE (Major Adverse Cardiovascular Events) comes up on this site
On GLP Watchdog, MACE comes up in 1 FDA warning letter. Browse the FDA warning letters.
Other terms under Major trials
Where the evidence lives
- Top GLP-1 cardiovascular studies
- The full GLP-1 glossary (149 terms, 8 categories)
- Research articles — written from primary sources
- Tools and calculators
- Compare GLP-1 telehealth providers